Brentuximab Vedotin in Combination with Nivolumab in CD30+Malignancies Refractory to Brentuximab Vedotin

Poh, C; Lynch, RC; Warren, EH; Ujjani, CS; Smith, SD; Shinohara, MM; Fromm, JR; Fan, XY; Voutsinas, JM; Wu, Q; Naylor, L; Rasmussen, H; Gopal, AK

BLOOD, 2023; 142 ():